Enrichment of adeno-associated virus serotype 5 full capsids by anion exchange chromatography with dual salt elution gradients.

Adeno-associated virus-based gene therapies have demonstrated substantial therapeutic benefit for the treatment of genetic disorders. In manufacturing processes, viral capsids are produced with and without the encapsidated gene of interest. Capsids devoid of the gene of interest, or "empty" capsids, represent a product-related impurity. As a result, a robust and scalable method to enrich full capsids is crucial to provide patients with as much potentially active product as possible. Anion exchange chromatography has emerged as a highly utilized method for full capsid enrichment across many serotypes due to its ease of use, robustness, and scalability. However, achieving sufficient resolution between the full and empty capsids is not trivial. In this work, anion exchange chromatography was used to achieve empty and full capsid resolution for adeno-associated virus serotype 5. A salt gradient screen of multiple salts with varied valency and Hofmeister series properties was performed to determine optimal peak resolution and aggregate reduction. Dual salt effects were evaluated on the same product and process attributes to identify any synergies with the use of mixed ion gradients. The modified process provided as high as ≥75% AAV5 full capsids (≥3-fold enrichment based on the percent full in the feed stream) with near baseline separation of empty capsids and achieved an overall vector genome step yield of >65%.

[1]  Hannah A. Blair Valoctocogene Roxaparvovec: First Approval , 2022, Drugs.

[2]  M. Biel,et al.  Comparison of Different Liquid Chromatography-Based Purification Strategies for Adeno-Associated Virus Vectors , 2021, Pharmaceutics.

[3]  Santoshkumar L. Khatwani,et al.  Anion-exchange HPLC assay for separation and quantification of empty and full capsids in multiple adeno-associated virus serotypes , 2021, Molecular therapy. Methods & clinical development.

[4]  Maryam T. Hussain,et al.  Characterization of Recombinant Adeno-Associated Viruses (rAAVs) for Gene Therapy Using Orthogonal Techniques , 2021, Pharmaceutics.

[5]  J. Schrag,et al.  Development of a scalable and robust AEX method for enriched rAAV preparations in genome-containing VCs of serotypes 5, 6, 8, and 9 , 2021, Molecular therapy. Methods & clinical development.

[6]  G. Berguig,et al.  Comprehensive characterization and quantification of adeno associated vectors by size exclusion chromatography and multi angle light scattering , 2021, Scientific Reports.

[7]  Thomas W. Powers,et al.  Adeno-associated virus capsid assembly is divergent and stochastic , 2020, Nature Communications.

[8]  John Pieracci,et al.  Separating Empty and Full Recombinant Adeno‐Associated Virus Particles Using Isocratic Anion Exchange Chromatography , 2020, Biotechnology journal.

[9]  Benjamin Adams,et al.  Moving from the bench towards a large scale, industrial platform process for adeno‐associated viral vector purification , 2020, Biotechnology and bioengineering.

[10]  Zeng-dian Zhao,et al.  Hofmeister Series: Insights of Ion Specificity from Amphiphilic Assembly and Interface Property , 2020, ACS omega.

[11]  T. Linke,et al.  Developing an Anion Exchange Chromatography Assay for Determining Empty and Full Capsid Contents in AAV6.2 , 2019, Molecular therapy. Methods & clinical development.

[12]  Wei-Chiang Chen,et al.  Analytical strategies for quantification of adeno-associated virus (AAV) empty capsids to support process development. , 2019, Human gene therapy methods.

[13]  Seng H. Cheng,et al.  Universal Method for the Purification of Recombinant AAV Vectors of Differing Serotypes , 2017, Molecular therapy. Methods & clinical development.

[14]  J. Heyda,et al.  Beyond the Hofmeister Series: Ion-Specific Effects on Proteins and Their Biological Functions. , 2017, The journal of physical chemistry. B.

[15]  T. Flotte Empty Adeno-Associated Virus Capsids: Contaminant or Natural Decoy? , 2017, Human Gene Therapy.

[16]  M. Jarrold,et al.  Resolving Adeno-Associated Viral Particle Diversity With Charge Detection Mass Spectrometry. , 2016, Analytical chemistry.

[17]  G. Liu,et al.  Interactions between Polyelectrolyte Brushes and Hofmeister Ions: Chaotropes versus Kosmotropes. , 2015, Langmuir : the ACS journal of surfaces and colloids.

[18]  R. Xu,et al.  Scalable Downstream Strategies for Purification of Recombinant Adeno-Associated Virus Vectors in Light of the Properties , 2015, Current pharmaceutical biotechnology.

[19]  Lin Zhao,et al.  Changes of Water Hydrogen Bond Network with Different Externalities , 2015, International journal of molecular sciences.

[20]  Michael A. Metrick,et al.  Hofmeister ion effects on the solvation and thermal stability of model proteins lysozyme and myoglobin , 2015 .

[21]  J. F. Wright,et al.  Product-Related Impurities in Clinical-Grade Recombinant AAV Vectors: Characterization and Risk Assessment , 2014, Biomedicines.

[22]  G. Gao,et al.  Empty virions in AAV8 vector preparations reduce transduction efficiency and may cause total viral particle dose-limiting side effects , 2014, Molecular therapy. Methods & clinical development.

[23]  M. R. Delgado Alvira,et al.  Analysis of particle content of recombinant adeno-associated virus serotype 8 vectors by ion-exchange chromatography. , 2012, Human gene therapy methods.

[24]  J. F. Wright,et al.  Separation of adeno-associated virus type 2 empty particles from genome containing vectors by anion-exchange column chromatography. , 2007, Journal of virological methods.

[25]  P. Cremer,et al.  Interactions between macromolecules and ions: The Hofmeister series. , 2006, Current opinion in chemical biology.

[26]  H. Mizukami,et al.  Removal of empty capsids from type 1 adeno-associated virus vector stocks by anion-exchange chromatography potentiates transgene expression. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[27]  J. F. Wright,et al.  Identification of factors that contribute to recombinant AAV2 particle aggregation and methods to prevent its occurrence during vector purification and formulation. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[28]  J. F. Wright,et al.  AAV empty capsids: for better or for worse? , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[29]  A. Kamen,et al.  Primary recovery and chromatographic purification of adeno-associated virus type 2 produced by baculovirus/insect cell system. , 2007, Journal of virological methods.